Trappe U, Riess H
Charité, Campus Virchow-Klinikum, Medizinische Klinik und Poliklinik, Augustenburger Plotz 1, 13353 Berlin.
Hamostaseologie. 2005 May;25(2):175-82. doi: 10.1267/hämo05020175.
Within the recent years preclinical and clinical investigations to a great extend increased the pathophysiological understanding what is going on in patients with severe sepsis. It became evident, that not the initiating infection by itself is the main reason for the severity and limited prognosis in sepsis. More important is the unbalanced reaction of the patient's organism to this infection, which is reflected in a mainly cytokine driven inflammation, the so called systemic inflammatory response syndrome, with its consequences. In the context of this syndrome released mediators, in part together with toxins from infectious microorganisms, result in a systemic activation of haemostasis. In the centre of our pathophysiologic model are the activations of the monocyte/macrophage-system and of the endothelium. This results in the activation of plasmatic cascades including the coagulation and fibrinolysis systems. The observed activation of haemostasis and inhibition of fibrinolysis in patients with sepsis by themselves interact with leukocytes and endothelium and play an important role in the progressive derangement of microcirculation. This is clinically reflected in organ dysfunctions. Within a single individual patient there is increased fibrin formation, decreases in coagulation factors, inhibitors and platelets, as well as defects of the fibrinolytic system in parallel that may clinically result in disseminated intravascular coagulation with the risk of bleeding complications in addition to organ dysfunctions.
近年来,临床前和临床研究在很大程度上增进了我们对严重脓毒症患者病理生理学的理解。显而易见,脓毒症病情严重及预后有限的主要原因并非初始感染本身。更重要的是患者机体对这种感染的失衡反应,这表现为主要由细胞因子驱动的炎症反应,即所谓的全身炎症反应综合征及其后果。在这种综合征的背景下,释放的介质,部分与感染性微生物产生的毒素一起,导致全身凝血激活。我们病理生理模型的核心是单核细胞/巨噬细胞系统和内皮细胞的激活。这导致包括凝血和纤溶系统在内的血浆级联反应激活。脓毒症患者中观察到的凝血激活和纤溶抑制自身与白细胞和内皮细胞相互作用,并在微循环的进行性紊乱中起重要作用。这在临床上表现为器官功能障碍。在单个患者体内,纤维蛋白形成增加、凝血因子、抑制剂和血小板减少,同时纤溶系统存在缺陷,这在临床上可能导致弥散性血管内凝血,除了器官功能障碍外还伴有出血并发症的风险。